EFTA02694296

DIRECTORS, OFFICERS, FOUNDERS AND ADVISORS Board of Directors: Kapil Dhingra, M.D Michael Gargano Colin Goddard, Ph.D Alan Lewis, Ph.D. Viren Mehta Mark Simon Management: Colin Goddard, Ph.D Executive Chairman USIDOCS7895963O Drug development expert, former head of Roche Oncology Leadership Team; led growth of oncology franchise from $800m to >$10 Billion per annum. Managing Director of Argent Ventures, real estate developer and investor in major US cities, primarily New York, LA and Miami. CEO of OSI Pharmaceuticals from 1998 until its $4B acquisition by Astellas Pharmaceuticals in June 2010; joined OSI as a scientist in 1989; presided over transition from $64M market cap to fully integrated biopharmaceutical company with $500M in revenue in 2010. Currently a director of Human Genome Sciences, Zelos and PanOptica. Chairman and CEO of Ambit Biosciences; previously President of Research at Celgene, CEO of Novocell, CEO of Signal Therapeutics, and VP of Research at Wyeth. 25+ year career advising biopharmaceutical industry worldwide: Founding Partner of Mehta Partners and earlier of Mehta & Islay; Management at Merck & Co.; Recently BOD at OS1 Pharmaceuticals. Former head of healthcare investment banking CitiGroup, renown biotech financier, has raised more than $30 Billion in public and private financings and many global strategic partnerships, current industry advisor. CEO of OSI Pharmaceuticals from 1998 until its $4B acquisition by Astellas Pharmaceuticals in June 2010; joined OSI as a scientist in 1989; presided over transition from $64M market cap to fully integrated biopharmaceutical company with $500M in revenue in 2010. Currently a director of Human Genome Sciences, Zelos and PanOptica. 22 EFTA_R1_02040903 EFTA02694296 Derek A. Small Interim/ founding CEO, Director Lee Arnold, PIED Chief Scientific Officer Jim Schulz Head of Finance Founding Scientists: Francis Barony, Ph.D. Founder, Chief Scientist Donald Bergstrom, Ph.D. Founder, Chief Chemist Maneesh Pingle, Ph.D Founder, Sr. Science Advisor usiooamsvar.r President of Luson Bioventures: focuses on starting new biotech ventures, drug developer of multiple molecules to human studies, raised >$50m in start up financing; part of early or founding management at Semafore Pharmaceuticals, Simdesk, Kinagen, Endgenitor, Naurex, and other start ups 22+ years in pharma discovery; former VP of US Research for OSI, inventor of Tarceva®, leading cancer drug >$1 Billion sales in 08, and 6 other molecules into clinical development; previously at Abbott, Pfizer. Partner in Upward Focus, LLC; over 20 years of experience in public accounting, Fortune 500 and start-up companies; focus expertise in outsourced financial support for small biotech companies including SonarMed Inc., Tigas Pharmaceuticals, and Naurex Inc. Professor at Weill Medical College of Cornell University; Inventor on 34 issued patents including ligase chain reaction (LCR) and others generating >$1.3B sales; >110 publications; numerous awards including Scientific American Top 50 Scientists in 2004; Ph.D. from Rockefeller 1981 Walther Professor of Medicinal Chemistry at Purdue University; 13 patents and >120 publications; numerous awards and advisor to several start-up biotechs; Chemistry Ph.D. from Berkley in 1970. Instructor at Weill Medical College of Cornell University in the department of Microbiology; Ph.D. from Purdue University in Medicinal Chemistry and Molecular Pharmacology. 23 EFTA_R1_02040904 EFTA02694297 Scientific Advisors: Paul Anderson, Ph.D Leading drug discovery expert, chemist, former head of discovery at, BMS and Merck/Dupont; awarded the ACS Priestley Medal, has discovered or developed several approved new drugs such as TRUSOPT, ZOCOR, CRIXIVAN and SUSTIVA that have achieved over $5 billion in aggregate annual sales. Homer L. Pearce, Ph.D Leading drug discovery expert, chemist, former head of oncology discovery & dev, Eli Lilly; awarded ACS Hero of Chemistry Award, has discovered or developed >25 clinical candidates and 3 FDA approved drugs with aggregate annual sales over $3 billion such as Gemzar, Alimta, and Oncotak. Charles Fisher, M.D. 35+ year career in clinical investigation and drug development: previously DVP, Global Pharmaceutical Development, Abbott Laboratories; Executive Director, Clinical Research Fellow, Eli Lilly (Xigris®); Professor and Head, Critical Care Medicine at the Cleveland Clinic Foundation Kama Dhingra, M.D Drug development expert, former head of Roche Oncology Leadership Team; led growth of oncology franchise from S800m to >$10 Billion per annum. 24 USIDOCS 7895963v3 EFTA_R1_02040905 EFTA02694298